MA25414A1 - Amides d'acide carboxylique de phenylcyclohexane qui ont un effet inhibiteur de fixation d'adenosine. - Google Patents

Amides d'acide carboxylique de phenylcyclohexane qui ont un effet inhibiteur de fixation d'adenosine.

Info

Publication number
MA25414A1
MA25414A1 MA26427A MA26427A MA25414A1 MA 25414 A1 MA25414 A1 MA 25414A1 MA 26427 A MA26427 A MA 26427A MA 26427 A MA26427 A MA 26427A MA 25414 A1 MA25414 A1 MA 25414A1
Authority
MA
Morocco
Prior art keywords
inhibitoring
phenylcyclohexane
effect
carboxylic acid
acid amides
Prior art date
Application number
MA26427A
Other languages
English (en)
Inventor
Wolf-Dietrich Freund
Stephan Nicholas Muller
Holger Paulsen
Ervin Horvath
Stephen Lensky
Jirg Keldenich
Joachim Schuhmacher
Original Assignee
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag filed Critical Bayer Ag
Publication of MA25414A1 publication Critical patent/MA25414A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/14—Radicals substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/18—Benzimidazoles; Hydrogenated benzimidazoles with aryl radicals directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/30—Nitrogen atoms not forming part of a nitro radical

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Anesthesiology (AREA)
  • Vascular Medicine (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
MA26427A 1999-05-29 2001-11-26 Amides d'acide carboxylique de phenylcyclohexane qui ont un effet inhibiteur de fixation d'adenosine. MA25414A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19924818A DE19924818A1 (de) 1999-05-29 1999-05-29 Substituierte Phenylcyclohexancarbonsäureamide

Publications (1)

Publication Number Publication Date
MA25414A1 true MA25414A1 (fr) 2002-04-01

Family

ID=7909712

Family Applications (1)

Application Number Title Priority Date Filing Date
MA26427A MA25414A1 (fr) 1999-05-29 2001-11-26 Amides d'acide carboxylique de phenylcyclohexane qui ont un effet inhibiteur de fixation d'adenosine.

Country Status (36)

Country Link
US (2) US6716849B1 (fr)
EP (1) EP1185516B1 (fr)
JP (1) JP2003500475A (fr)
KR (1) KR20020003397A (fr)
CN (1) CN1200932C (fr)
AR (1) AR024100A1 (fr)
AT (1) ATE238997T1 (fr)
AU (1) AU765752B2 (fr)
BG (1) BG106107A (fr)
BR (1) BR0011061A (fr)
CA (1) CA2375186A1 (fr)
CZ (1) CZ20014288A3 (fr)
DE (2) DE19924818A1 (fr)
DK (1) DK1185516T3 (fr)
EE (1) EE200100634A (fr)
ES (1) ES2197870T3 (fr)
GT (1) GT200000083A (fr)
HK (1) HK1048810A1 (fr)
HN (1) HN2000000072A (fr)
HR (1) HRP20010955A2 (fr)
HU (1) HUP0201350A3 (fr)
IL (1) IL146392A0 (fr)
MA (1) MA25414A1 (fr)
MX (1) MXPA01012241A (fr)
MY (1) MY122576A (fr)
NO (1) NO20015810L (fr)
PE (1) PE20010167A1 (fr)
PL (1) PL352101A1 (fr)
PT (1) PT1185516E (fr)
RU (1) RU2246490C9 (fr)
SI (1) SI1185516T1 (fr)
SK (1) SK17052001A3 (fr)
SV (1) SV2004000087A (fr)
UA (1) UA73126C2 (fr)
WO (1) WO2000073275A1 (fr)
ZA (1) ZA200109263B (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1609784A1 (fr) * 2004-06-25 2005-12-28 Boehringer Ingelheim Pharma GmbH & Co.KG Procédé pour la préparation de 4-(benzimidazolylméthylamino)-benzamidines
CN1834090B (zh) * 2005-03-18 2011-06-29 中国科学院上海药物研究所 苯并咪唑类化合物、其制备方法以及用途
CA2874303C (fr) 2012-06-11 2020-10-13 Ucb Biopharma Sprl Benzimidazoles modulant l'activite tnf -alpha
SG11202105512PA (en) * 2018-11-25 2021-06-29 Tnt Medical Corp Orally active prodrug of gemcitabine

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2685918B1 (fr) * 1992-01-08 1995-06-23 Union Pharma Scient Appl Nouveaux derives de l'adenosine, leurs procedes de preparation, compositions pharmaceutiques les contenant.
DE4221009A1 (de) * 1992-06-26 1994-01-05 Bayer Ag Imidazolyl-substituierte Cyclohexanderivate
ATE174913T1 (de) 1992-07-31 1999-01-15 Bristol Myers Squibb Co Diphenyl oxazole-, thiazole- und imidazole- derivate als inhibitoren der wiederaufnahme des adenosins
DE4304455A1 (de) * 1993-02-15 1994-08-18 Bayer Ag Heterocyclisch substituierte Phenyl-cyclohexan-carbonsäurederivate
DE4401893A1 (de) * 1994-01-24 1995-07-27 Bayer Ag Substituierte Arylharnstoffe
DE19503160A1 (de) * 1995-02-01 1996-08-08 Bayer Ag Verwendung von Phenylcyclohexylcarbonsäureamiden
HRP960015B1 (en) 1995-02-01 2000-12-31 Bayer Ag Substituted indole derivatives

Also Published As

Publication number Publication date
SV2004000087A (es) 2004-05-07
AU4405500A (en) 2000-12-18
MY122576A (en) 2006-04-29
CA2375186A1 (fr) 2000-12-07
PT1185516E (pt) 2003-09-30
HRP20010955A2 (en) 2003-08-31
CZ20014288A3 (cs) 2002-03-13
US6716849B1 (en) 2004-04-06
PL352101A1 (en) 2003-07-28
HUP0201350A3 (en) 2003-05-28
EP1185516B1 (fr) 2003-05-02
MXPA01012241A (es) 2002-08-12
SK17052001A3 (sk) 2002-06-04
DK1185516T3 (da) 2003-08-11
CN1365356A (zh) 2002-08-21
EE200100634A (et) 2003-02-17
NO20015810D0 (no) 2001-11-28
SI1185516T1 (en) 2003-10-31
ATE238997T1 (de) 2003-05-15
RU2246490C9 (ru) 2005-09-20
AR024100A1 (es) 2002-09-04
ZA200109263B (en) 2003-01-29
NO20015810L (no) 2002-01-25
AU765752B2 (en) 2003-09-25
HN2000000072A (es) 2001-02-02
EP1185516A1 (fr) 2002-03-13
CN1200932C (zh) 2005-05-11
BG106107A (bg) 2002-05-31
DE50001982D1 (de) 2003-06-05
RU2246490C2 (ru) 2005-02-20
HUP0201350A2 (en) 2002-08-28
US20040186106A1 (en) 2004-09-23
IL146392A0 (en) 2002-07-25
UA73126C2 (en) 2005-06-15
ES2197870T3 (es) 2004-01-16
JP2003500475A (ja) 2003-01-07
KR20020003397A (ko) 2002-01-12
DE19924818A1 (de) 2000-11-30
PE20010167A1 (es) 2001-04-25
HK1048810A1 (zh) 2003-04-17
BR0011061A (pt) 2002-03-05
GT200000083A (es) 2001-11-17
WO2000073275A1 (fr) 2000-12-07

Similar Documents

Publication Publication Date Title
MA24488A1 (fr) Derives d'acide hexanoique nouveaux .
DZ2800A1 (fr) Nouveau dérivé de l'acide 3-aryl-2-hydroxypropionique.
DE69823214D1 (de) Kit zur Längenbestimmung von Kathetern vor ihrer Einführung
TR199802106A3 (tr) Sübstitüe edilmis izokinolin-3-karbon asidi amidleri.
IS5619A (is) (4-Arýlsúlfónýlamínó) -tetrahýdrópýran-4-karboxýlsýru hýdroxamíð
MA27041A1 (fr) Derives d'acide dicarboxylique aromatique
MA26616A1 (fr) Derives de l'acide phenoxyacetique et du phenoxymethyltetrazole ayant une activite antitumorale
FI955130A0 (fi) L-aminohappo-oksidaasi
DE59710386D1 (de) Torflagge für den skisport
GB0103111D0 (en) Treatment of fibromyalgia with ubiquinone 10 or succinic acid
DE69730800D1 (de) Oxaalkylcarbonsäure-modifizierte Epoxysiliconzusammensetzungen
ZA975755B (en) Useful formulations of acid addition salt drugs.
NO20005164L (no) 2-metylpropionsyre-derivater og medisinske sammensetninger inneholdende det samme
MA23133A1 (fr) Derives d'acide d'acyloxyhexanoique .
DK0929517T3 (da) Hydroxamsyrederivater
NO924465L (no) Kinolylmetoksyfenyl-eddiksyreamider
ATE212975T1 (de) Carbamoylcarbonsäureamidoxime
IL146392A0 (en) Substituted phenylcyclohexane carboxylic acid amides that have an adenosine uptake inhibiting effect
FR2769624B1 (fr) Procede de preparation d'acide carboxylique
FR2758629B1 (fr) Procede de recalage d'images sonar au moyen de sous-antennes
AT5066U3 (de) Torflagge für den skisport
FR2717540B1 (fr) Gaine d'ancrage.
UA2995S (uk) Тренажер "тяга зверху"
UA2992S (uk) Тренажер "тяга знизу"
FR2789903B1 (fr) Amelioration d'une fixation de ski de fond